Wellington Management Group LLP Sells 28,214 Shares of MBX Biosciences, Inc. (NYSE:MBX)

Wellington Management Group LLP lowered its position in shares of MBX Biosciences, Inc. (NYSE:MBX) by 1.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,909,639 shares of the company’s stock after selling 28,214 shares during the period. Wellington Management Group LLP owned 8.71% of MBX Biosciences worth $52,992,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Corebridge Financial Inc. purchased a new position in shares of MBX Biosciences during the 4th quarter valued at $103,000. JPMorgan Chase & Co. bought a new stake in MBX Biosciences during the fourth quarter valued at $168,000. Rhumbline Advisers purchased a new position in MBX Biosciences during the fourth quarter worth about $175,000. BIT Capital GmbH bought a new position in MBX Biosciences in the 4th quarter worth about $235,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of MBX Biosciences in the 3rd quarter valued at about $405,000.

MBX Biosciences Price Performance

Shares of NYSE MBX opened at $6.04 on Friday. The business has a 50-day moving average of $9.49 and a 200-day moving average of $16.28. MBX Biosciences, Inc. has a 12 month low of $5.66 and a 12 month high of $27.50.

Insider Buying and Selling at MBX Biosciences

In related news, CEO P. Kent Hawryluk acquired 50,000 shares of the stock in a transaction dated Tuesday, February 4th. The shares were purchased at an average price of $10.69 per share, for a total transaction of $534,500.00. Following the transaction, the chief executive officer now owns 448,277 shares in the company, valued at $4,792,081.13. This represents a 12.55 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Carl L. Gordon bought 47,502 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average price of $9.87 per share, with a total value of $468,844.74. Following the completion of the transaction, the director now directly owns 3,205,930 shares of the company’s stock, valued at $31,642,529.10. This represents a 1.50 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 240,672 shares of company stock worth $2,555,308 over the last three months.

MBX Biosciences Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.